Valuation: Xspray Pharma AB

Market Cap 650M 67.79M 58.8M 55.15M 50.24M 94.54M 6.46B 96.02M 253M 3.24B 254M 249M 10.89B P/E 2026 *
-2.21x
P/E 2027 * 4.15x
Enterprise Value 650M 67.79M 58.8M 55.15M 50.24M 94.54M 6.46B 96.02M 253M 3.24B 254M 249M 10.89B EV / Sales 2026 *
33.7x
EV / Sales 2027 * 1.15x
Free-Float
85.26%
Yield 2026 *
-
Yield 2027 * -
1 day-0.72%
1 week-17.47%
Current month-18.84%
1 month-8.30%
3 months-43.74%
6 months-43.27%
Current year-56.44%
1 week 13.4
Extreme 13.4
15.5
1 month 13.4
Extreme 13.4
17.24
Current year 13.4
Extreme 13.4
32.5
1 year 13.4
Extreme 13.4
64.1
3 years 13.4
Extreme 13.4
91.7
5 years 13.4
Extreme 13.4
147.2
10 years 13.4
Extreme 13.4
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Tech/Sci/R&D Officer 73 2022-12-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap.
4/22/26 Buy

Director

810 0.0019%
4/22/26 Sell

Director

4 0.0000%
9/19/25 Buy

Director

2,063 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%-17.47%-73.29%-57.19% 68.79M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+4.53%+37.56%+67.36% 54.05B
-0.22%+33.95%+17.18%+489.75% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
-0.06%+1.52%-15.12%-13.26% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+8.47%+50.06%-20.09% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-1.85%-10.04%+34.67%+134.11% 12.72B
Average -0.17%+6.60%+46.54%+175.76% 26.68B
Weighted average by Cap. +0.02%+10.11%+57.45%+165.94%

Financials

2026 *2027 *
Net sales 19.3M 2.01M 1.75M 1.64M 1.49M 2.81M 192M 2.85M 7.52M 96.4M 7.56M 7.4M 324M 564M 58.85M 51.05M 47.88M 43.62M 82.08M 5.61B 83.36M 220M 2.82B 221M 216M 9.46B
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-08-12 SEK 13.70 -0.72% 56,364
26-08-11 SEK 13.80 -3.77% 132,818
26-08-10 SEK 14.34 -4.53% 133,638
26-08-07 SEK 15.02 +2.04% 103,473
26-08-06 SEK 14.72 -4.66% 87,646

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock